TELO

Telomir Pharmaceuticals, Inc. Common Stock

News

accessnewswire.comTelomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Modelaccessnewswire.comJun 15

accessnewswire.comTelomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Diseaseaccessnewswire.comMay 20

accessnewswire.comTelomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Canceraccessnewswire.comApr 30

defenseworld.netTelomir Pharmaceuticals (NASDAQ:TELO) Trading 1.4% Higher – Here’s What Happeneddefenseworld.netApr 25

accessnewswire.comTelomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)accessnewswire.comApr 24

Trade TELO

About Telomir Pharmaceuticals, Inc. Common Stock

Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.

CEO: Erez Aminov
IPO Date: Apr 9, 2019

Market Data

Open: $1.29
High: $1.43
Low: $1.29
Volume: 1.1M
Avg Volume: 136.5K
52W High: $3.10
52W Low: $1.05

Valuation

Market Cap: $49M
Enterprise Value: $43M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-3.7M
Revenue: $0
Net Income: $-10M
Cash: $7.3M
Debt: $0

Events

EarningsSep 2

EPS est. -0.07